United States: Weeks Defies Years Of Jurisprudence, Allowing Innovator Liability For Generic Drugs

Last week the Alabama Supreme Court adopted brand-name manufacturer liability for a generic drug sold by another company, becoming the first state supreme court to do so. Wyeth, Inc. v. Weeks, No. 1101397 (Ala. Jan. 11, 2013). The court held that a generic drug user could foreseeably rely on a brand-name drug warning and maintain a failure to warn claim against the brand-name manufacturer, even when the plaintiff did not ingest that manufacturer's drug.

CERTIFIED QUESTION FROM DISTRICT COURT

Danny and Vicki Weeks filed suit against four pharmaceutical companies in federal district court, alleging injury from long-term use of metoclopramide, the generic form of Reglan. They claimed that Mr. Weeks ingested generic metoclopramide manufactured by Teva and Actavis. Plaintiffs also named Wyeth and Schwarz, the manufacturers of brand-name Reglan, even though they never alleged that Mr. Weeks ingested the brand-name drug. Instead, they sued Wyeth and Schwarz on a theory that the brand-name manufacturers had a duty to warn all users of the drug based on federal requirements that all generic labels be identical to the brand-name label. Faced with this question and conflicting precedent, the district court certified the question to the Alabama Supreme Court, specifically:

Under Alabama law, may a drug company be held liable for fraud or misrepresentation (by misstatement or omission), based on statements it made in connection with the manufacture or distribution of a brand-name drug, by a plaintiff claiming physical injury from a generic drug manufactured and distributed by a different company?

The Alabama Supreme Court answered in the affirmative, joining a small group of courts to do so. Cf. Conte v. Wyeth, 168 Cal. App. 4th 89 (2008); Kellogg v. Wyeth, 612 F. Supp. 2d 421 (D. Vt. 2008).

MENSING SETS THE STAGE

The court began its analysis with a discussion of Wyeth v. Levine, 555 U.S. 555 (2009), and PLIVA v. Mensing, 131 S.Ct. 2567, 564 U.S. __ (2011), highlighting "the seeming contradiction in preemption claims against a generic manufacturer in PLIVA but allowing state-law tort claims in Wyeth." The court also examined several federal court decisions applying Alabama law, which had found that brand drug manufacturers may not be held liable to a plaintiff who ingested a generic drug. See Mosley v. Wyeth, 719 F. Supp. 2d 1340 (S.D. Ala. 2010); Overton v. Wyeth, Inc., No. CA 10-0491-KD-C (S.D. Ala. Mar. 15, 2011); Simpson v. Wyeth, Inc., No. 7:10-cv-01771-HGD (N.D. Ala. Dec. 9, 2010).

Common to these federal court decisions was their holding that generic drug manufacturers were responsible for the content of their own labels. However, these cases preceded Mensing, which held that generic drug labels had to be the same as their branded counterparts. 131 S.Ct. at 2581. This "sameness" requirement was crucial to the Alabama Supreme Court's finding.

FORESEEABILITY

The court recognized it was adopting the minority view and that the majority view followed Foster v. American Homes Products Corp., 29 F.3d 165 (4th Cir. 1994). In Foster, the Fourth Circuit held that a brand-name manufacturer owed no duty to users of generic drugs. The Foster court began with the pre-Mensing premise that a generic manufacturer was responsible for the content of its own label and concluded that to impose a duty on the brand-name manufacturer for the content of generic labels would "stretch the concept of foreseeability too far."

The Alabama Supreme Court found that this logic should be limited to a strict liability claim arising out of a defect in production (i.e., not a failure to warn). Such a defect would only foreseeably harm a user of the manufacturer's product. Not so for a warning claim, particularly post-Mensing: "an omission or defect in the labeling for the brand-name drug would necessarily be repeated in the generic labeling, foreseeably causing harm to a patient who ingested the generic product." Weeks, slip op. at 41.

FOLLOWING CONTE

In finding that generic users foreseeably rely on brand-name labels, the Weeks court followed the reasoning first set forth by the California Court of Appeals in Conte v. Wyeth, Inc., 168 Cal. App. 4th 89. Though often derided by the defense bar and other courts as illogical, the Conte court provided ample bases in traditional tort principles for its then-novel finding that generic users would foreseeably rely on the brand-name drug's warnings. Because the generic and brand-name drugs were required to be identical, it was entirely foreseeable that a physician would rely on the brand-name drug's warning in prescribing a generic drug. It was also foreseeable that the pharmacist would substitute the generic as permitted or required by state law or insurance, even if the brand-name drug had originally been prescribed.

Similar logic was applied in Vermont in Kellogg v. Wyeth, 762 F. Supp. 2d 694, another case finding that a brand-name manufacturer could potentially be liable to a generic user. The Kellogg court denied defendant's motion for summary judgment in order to allow the trier of fact to determine whether the plaintiff's doctor had in fact relied on the brand-name label in prescribing the drug at issue.

What the Weeks court did not address was whether Conte still applies in California in light of the California Supreme Court's subsequent clarification that "the foreseeability of harm, standing alone, is not a sufficient basis for imposing strict liability" on a manufacturer for another company's product. O'Neil v. Crane Co., 53 Cal. 4th 335, 362 (2012). However, a federal district court in Kentucky, applying California law, distinguished O'Neil from a Conte-like fact pattern involving innovator liability and found that the plaintiffs could pursue their claims against the brand-name manufacturer. In re Darvocet, Darvon and Propoxyphone Prods. Liab. Litig., No. 2:11-md-2226-DCR, 2012 WL 3842271, at *6 (E.D. Ky. Sept. 5, 2012). Moreover, the Ninth Circuit recognized Conte as the law of the state, citing it for the proposition that "California's negligence law may impose on a manufacturer a duty to warn individuals who, while not users of its products, could foreseeably rely on its warnings." Rosa v. TASER Int'l, Inc., 684 F.3d 941, 949 (9th Cir. 2012).

NOTIONS OF FUNDAMENTAL FAIRNESS

Given the state of pharmaceutical product liability law and the perceived injustice established by Mensing, it seemed only a matter of time before more courts began embracing Conte. While this logic is often criticized, tort law is replete with examples of defendants being held liable to plaintiffs with whom they had no relationship. This absence of privity is one of the hallmarks of tort law, which is defined instead by foreseeability and the "zone of danger."

For example, construction companies have been held liable for injuries to children on their equipment when the children are mischievous trespassers. Courts that have not followed traditional tort analysis have found that innovator liability goes "too far." However, it is certainly possible that other courts will allow for innovator liability based on traditional tort theories.

In reality, courts are struggling to balance two perceived injustices. On the one hand, there is the unfairness of leaving patients who use generic drugs (often through no choice of their own through substitution at the pharmacy) without any remedy for their injuries. This unfortunate landscape was recognized by Justice Thomas, writing for the majority in Mensing, and ridiculed by Justice Sotomayor in her vehement dissent. On the other hand, courts are reluctant to hold a brand-name manufacturer liable when it had no role in making the drug in question.

Ultimately, the Weeks court concluded that "it is not fundamentally unfair to hold the brand-name manufacturer liable for warnings on a product it did not produce" where plaintiffs bring "misrepresentation theories based . . . on information and warning deficiencies, when those alleged misrepresentations were drafted by the brand-name manufacturer and merely repeated by the generic manufacturer."

RELIEF FOR GENERIC DRUG PLAINTIFFS?

The holding in Weeks remains the minority view, significantly outnumbered by the "traditional' products liability theory represented by Foster. However, Weeks is now the law of Alabama and constitutes binding precedent for any pharmaceutical product liability cases filed there. The possibility remains that more states will follow. Plaintiffs could potentially reap enormous benefits from this holding, particularly in situations involving multiple manufacturers where product identification has historically caused plaintiffs problems.

In California, where Conte remains the highest state court opinion on the issue, brand-name manufacturers can assert a number of Rowland factors to override foreseeability, the factor given the greatest weight by the Conte court. See Rowland v. Christian, 69 Cal. 2d 108, 113 (Cal. 1968). Other factors not considered in depth in Conte include the "moral blame" associated with defendant's conduct, burden to defendant, consequences to the community, and the availability and cost of insurance, all of which favor dismissal of the brand-name manufacturer.

Still, under Conte and Weeks, plaintiffs can survive a motion to dismiss and seek to hold the brand-name manufacturer liable for failure to warn even where product identification is impossible. This could significantly impact brand-name manufacturers, especially those with small market share who historically enjoyed an exit strategy based on product identification. Because of this there may be more filings against brand-name manufacturers, both in Alabama and nationwide, as plaintiffs try to make Conte and Weeks the law of every state.

Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Morrison & Foerster LLP. All rights reserved

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Erin M. Bosman
Julie Y. Park
 
In association with
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Emails

From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

*** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.